Axsome Therapeutics shares are trading higher the company's AXS-12 achieved primary endpoint in the SYMPHONY phase 3 trial in narcolepsy.
Portfolio Pulse from Benzinga Newsdesk
Axsome Therapeutics' stock is trading higher after its AXS-12 drug successfully met the primary endpoint in the SYMPHONY phase 3 trial for treating narcolepsy.
March 25, 2024 | 10:41 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Axsome Therapeutics' shares are experiencing an uptick following the successful phase 3 trial results of AXS-12 for narcolepsy.
The positive outcome from the SYMPHONY phase 3 trial of AXS-12 for narcolepsy directly impacts Axsome Therapeutics' market perception and investor confidence, likely leading to a short-term increase in its stock price. Successful trial results often lead to increased investor optimism about the drug's commercial potential and the company's growth prospects.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100